Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2025)

Spero Therapeutics' Return on Capital Employed history spans 9 years, with the latest figure at 0.12% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 105.0% year-over-year to 0.12%; the TTM value through Dec 2025 reached 0.12%, up 105.0%, while the annual FY2025 figure was 0.08%, 78.0% up from the prior year.
  • Return on Capital Employed reached 0.12% in Q4 2025 per SPRO's latest filing, up from 0.94% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.21% in Q4 2023 to a low of 2.0% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.54%, with a median of 0.61% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: plummeted -131bps in 2022, then soared 202bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.63% in 2021, then increased by 20bps to 0.51% in 2022, then surged by 141bps to 0.21% in 2023, then plummeted by -544bps to 0.93% in 2024, then surged by 113bps to 0.12% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Return on Capital Employed are 0.12% (Q4 2025), 0.94% (Q3 2025), and 0.96% (Q2 2025).